1. Home
  2. OBDC vs SYRE Comparison

OBDC vs SYRE Comparison

Compare OBDC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Owl Capital Corporation

OBDC

Blue Owl Capital Corporation

HOLD

Current Price

$11.82

Market Cap

5.6B

Sector

Finance

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$71.70

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBDC
SYRE
Founded
2015
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.9B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
OBDC
SYRE
Price
$11.82
$71.70
Analyst Decision
Buy
Strong Buy
Analyst Count
8
12
Target Price
$14.00
$85.08
AVG Volume (30 Days)
3.9M
1.3M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
13.40%
N/A
EPS Growth
N/A
N/A
EPS
1.24
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.52
$12.29
52 Week High
$15.19
$76.00

Technical Indicators

Market Signals
Indicator
OBDC
SYRE
Relative Strength Index (RSI) 60.34 63.98
Support Level $11.65 $30.39
Resistance Level $12.10 $74.92
Average True Range (ATR) 0.28 4.18
MACD 0.05 -0.71
Stochastic Oscillator 84.70 55.65

Price Performance

Historical Comparison
OBDC
SYRE

About OBDC Blue Owl Capital Corporation

Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: